- Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical Data
- The Patent further describes Algorithms to help Determine Safety Levels of Food Ingredients, Offering a Personalized Approach to Dietary Interventions and Safety
IRVINE, Calif., June 21, 2023 (GLOBE NEWSWIRE) — Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative diagnostic solutions, announced that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a patent application that covers a development stage information technology (“IT”) system that includes an artificial Intelligence (AI) claim aimed at assisting individuals to protect themselves against potential adverse reactions to specific food ingredients. Among other things, the patent claims focus on systems, algorithms and methods to help patients avoid potentially harmful food items based on their unique medical data.
The patent encompasses a host of IT methods to evaluate, predict, learn and update the potential health risks associated with consuming specific prepared food items, based on a patient’s medical data. By deriving a confidence level from the patient’s health records including a patient’s elevated immune response to specific food ingredients, including those identified through the Biomerica inFoods® IBS test, or other foods that cause adverse reactions such as gluten intolerance, an IT system could be designed to assess the likelihood of an adverse reaction to a common packaged or prepared food that may contain the food ingredient the patient needs to avoid.
Leveraging two sets of data, the invention formulates a safety level for each food item in each specific patient. Consequently, a system could be designed to enable an application (App) on a phone, iPad or computer to screen packaged or prepared foods to identify if the packaged or prepared food contains an ingredient previously identified as harmful to the patient. The technology could also recommend alternative packaged or prepared foods that do not contain the previously identified harmful food ingredient.
This patented approach could bridge the gap between healthcare and diet, designed to allow individuals with a variety of medical conditions, allergies, illnesses and food intolerances, whose symptoms are caused or exasperated by consumption of specific food ingredients, to have more control and confidence in their dietary choices. The technology described in this patent that has been issued the notice of allowance can contribute significantly to the digital health sector, ushering in a new era of personalized and preventive healthcare through the power of technology.
This patent further strengthens the Company’s robust intellectual property portfolio in the area of science, diet and technology. This is the second patent on this technology the company has received, the first was issued in Japan.
“This notice of patent allowance is a step towards a safer, more informed environment where individuals can confidently navigate their dietary choices.” said Zack Irani the CEO of Biomerica. “This recognition from the Chinese Patent Office of the novel and inventive nature of this technology marks a significant step forward in our longer-term ambition of facilitating happier healthier lives globally.”
The allowed patent application number in China is 201680054790.9 and can be viewed at: https://biomerica.com/inFoods/our-technology/
About inFoods IBS:
Unlike traditional IBS treatments that rely on medications to mask symptoms, inFoods® IBS is a personalized and natural treatment approach. The inFoods IBS test is based on a patented technology that identifies the specific foods that can trigger IBS symptoms in individual patients. Once the trigger food(s) have been identified, patients who remove these trigger foods from their diets often experience a significant reduction or elimination in their IBS symptoms. A double blinded placebo controlled clinical study (performed at Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, the University of Michigan, Houston Methodist Hospital, and others), showed the inFoods® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API). Symptom improvement in API for patients in the treatment arm versus the placebo arm was similar to, and in some cases better than, the improvement seen from current IBS drugs in the market, but without the drug side effects. Further information about Biomerica’s patented inFoods® Products and Technology Platform can be found at: https://biomerica.com/infoods/
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to: the possibly future development of an information technology system that utilizes artificial intelligence to guide a patient’s dietary choices, and the market opportunities from such a system; the Company’s intellectual property; inFoods® IBS test and other tests; allowance and or clearance of patent applications in China and in other countries; FDA or other regulatory clearance or possible future clearance of products that can be developed and commercialized, utilizing the technology described in the Company’s patent applications; the novel nature of the patented technology and the freedom to operate within the field of use described in patent applications; the development of systems incorporating the patented technology; and the assessment capabilities of a system to detect potential adverse reactions. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of products incorporating the patented technology; regulatory approvals necessary prior to commercialization any of the Company’s products; commercial acceptance of products incorporating the patented technology; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them and such other risks disclosed in the our reports (such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K) filed with the SEC and available on the SEC’s Internet site (http://www.sec.gov). Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The Company is under no obligation to update any forward-looking statements after the date of this release.
Source: Biomerica, Inc.